Project Oncology®

HER3 is the new marker on the block, but is it diagnostic, predictive, or prognostic? Hear from the experts, Drs. Lauren Ritterhouse, Pasi Jänne, and Kanwal Raghav, as they explore the role of HER3 in oncogenesis and resistance to EGFR TKIs. Find out how we can now target HER3 signaling in metastatic solid tumors through the use of emerging HER3-targeted therapies along with novel and exciting antibody-drug conjugate studies and strategies.

What kind of role does next-generation sequencing play in HER2-mutated non-small cell lung cancer? Dr. Jacob Sands is joined by Dr. Tejas Patil from the University of Colorado Medicine to explore the clinical utility of NGS and highlight opportunities to expand molecular testing into clinical practice.

While the management and treatment of HER2-mutated non-small cell lung cancer continues to evolve, patients still face many unmet needs. Dr. Nicolas Girard, a pneumologist and Professor of Respiratory Medicine at Versailles Saint Quentin University, explores these unmet needs and how we can solve them.

What do the NCCN guidelines recommend for the management of patients with chronic lymphocytic leukemia, or CLL, and mantle cell lymphoma, or MCL? Dr. Charles Turck is joined by Dr. Thomas Kipps to talk about prognostic risk indicators, current therapeutic agents, and adverse events for patients with CLL and MCL.

Has the COVID-19 pandemic limited our treatment options for patients with mantle cell lymphoma? To answer this, Dr. Thomas Kipps reviews key treatment challenges and considerations for these patients amid the ongoing pandemic.

When determining a patient’s therapy regimen, what disease-related factors do we need to keep in mind? Dr. Nicole Lamanna, a Hematologist/Oncologist at Columbia University Medical Center, share strategies for tailoring chronic lymphocytic leukemia treatment and how that can impact patient outcomes.

For patients with advanced non-small cell lung cancer, broad molecular testing can be both a solution and a challenge. Here to share key challenges for next-generation sequencing is Dr. Jack West, Associate Clinical Professor at the City of Hope Comprehensive Cancer Center in California.

As the field of chronic lymphocytic leukemia continues to evolve, what we can look forward to seeing at the 63rd American Society of Hematology Annual Meeting and Exposition? Dr. Lindsey Roeker shares what she expects to see at this year’s ASH meeting.

FLAURA and RELAY have changed the landscape of treatment in EGFR-mutant advanced non-small cell lung cancer (NSCLC). But how do know which patients will benefit from these important advances in our knowledge of treating these cancers in the first and subsequent lines of therapy? Join Drs. Mark Socinski and John Heymach as they examine a patient case and discuss the “art” of treatment selection and sequencing of therapy. They also dive into recent advances in the dual blockade of antiangiogenics and TKIs in the frontline setting. Tune in to keep up!

For patients with chronic lymphocytic leukemia, molecular analysis can provide critical information. Dr. John C. Byrd discusses the importance of IGHV and TP53 sequencing and the clinical value they provide.